Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4652W HIGH $49.25
Volume
877.97 K
Value Traded
97.07 K
Short % Float
0.62%
-0.46%Week
-51.58%1 Month
-71.98%3 Month
-80.13%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.75 M
EPS (TTM)
-8.28
P/E Ratio
-
Ent. Value
1.12 M
Total Shares
3.50 M
Float Shares
4.66 M
Insiders
26.44%
Institutions
0.76%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PPCB Catalyst Timeline
Dated clinical, regulatory and corporate events for Propanc Biopharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Propanc Biopharma, Inc.
93Total events
14Upcoming
8Tier-1 (high impact)
2014 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Manufacturing MilestonePRPCMC / Inspection
Two scale-up runs scheduled for PRP manufacturing
▲Preclinical PoCPRPPreclinical
PRP shows >90% tumor growth inhibition and >2.5-fold survival benefit in PDAC models
pancreatic ductal adenocarcinoma (PDAC)source ↗
▲Fast Track DesignationERAS-0015Designation
FDA Fast Track designation for ERAS-0015 in metastatic pancreatic adenocarcinoma
metastatic pancreatic adenocarcinomasource ↗
●Trial InitiationPRPTrial
Feasibility assessment for Phase 1b study of PRP
advanced solid tumorssource ↗
▲Preclinical PoCPRPPreclinical
PRP shows >90% tumor growth inhibition and >2.5-fold survival benefit in PDAC models
pancreatic ductal adenocarcinomasource ↗
●PublicationPresentation
Publication of evaluation of recombinant trypsinogen and chymotrypsinogen in Microbial Cell Factories
●Development Candidate NominationRec-PRPPreclinical
Recombinant proenzyme product candidate rec-PRP designated as follow-on to PRP
metastatic cancer from solid tumorssource ↗
▲Partnership / LicensePRPCorporate
Signed MOU with Avance Clinical for Phase 1b trial of PRP
advanced solid tumorssource ↗
◆ATM ProgramCorporate
Initiated $5.0 million share repurchase program with first tranche of up to $500,000 over 30 days
◆Trial InitiationPRPTrial
Phase 1b study initiation in advanced cancer patients with solid tumors
advanced solid tumorssource ↗
●Manufacturing MilestonePRPCMC / Inspection
Manufacturing PRP for upcoming clinical trial expected to complete in Q3 2026
◆Biomarker DataPRPClinical Data
Bioanalytical method validation to measure PRP PK expected to complete in Q3 2026
●IND SubmissionPRPIND
Clinical trial application preparation for ethics committee submission at Peter MacCallum expected to complete in Q3 2026
advanced solid tumorssource ↗
▲Topline ReadoutERAS-0015Clinical Data
July 2026 update reporting 57% unconfirmed 8-week ORR at 32 mg in 2L+ KRAS G12X PDAC
second-line or later KRAS G12X PDACsource ↗
◆Trial InitiationPRPTrial
PRP Phase 1b First-In-Human study in advanced cancer patients on schedule to enter
advanced cancersource ↗
▲Manufacturing MilestonePRPCMC / Inspection
Engaged European CDMO for GMP production of PRP
advanced cancer patients suffering from solid tumorssource ↗
▲Partnership / LicenseCorporate
Multi-year Joint Research Collaboration Agreement with Universities of Jaén and Granada, Spain
▲Preclinical PoCPRPPreclinical
PRP shows >85% tumor growth inhibition in preclinical pancreatic models
pancreatic cancersource ↗
▲Patent GrantedIP / Competition
Filed four provisional patent applications with IP Australia for proenzyme formulations
▲PublicationPRPPresentation
Published impact of proenzymes on PDAC fibroblasts in Scientific Reports
pancreatic ductal adenocarcinomasource ↗
▼Equity OfferingCorporate
Entered into $100 million private placement agreement; received initial $1M and additional $500K
◆Trial InitiationPRPTrial
Preparing for Phase 1b First-In-Human study in advanced cancer patients
advanced cancersource ↗
●Quarterly UpdateCorporate
Reported half yearly financial results for period ending December 31, 2025
▲Composition Patent FiledPRPIP / Competition
Filed fourth provisional patent application for PRP formulations with IP Australia
recurrent and metastatic cancersource ↗
●Composition Patent FiledPRPIP / Competition
Filed new provisional patent application for methods of producing trypsinogen and chymotrypsinogen with IP Australia
metastatic cancersource ↗
▲Patent GrantedIP / Competition
Three recently filed patent applications entering national phase across multiple jurisdictions
▲PublicationPRPPresentation
Publication of impact of proenzymes on PDAC fibroblasts in Scientific Reports
pancreatic ductal adenocarcinomasource ↗
▲Patent GrantedPRPIP / Competition
Patent application filed for PRP-based treatment method for fibrotic disease
fibrotic diseasesource ↗
▲PublicationPresentation
Fifth peer-reviewed scientific publication accepted in Scientific Reports
▲Program DiscontinuationCorporate
Ongoing investigations into PRP for treatment of fibrosis announced last month
fibrosissource ↗
▲Quarterly UpdateCorporate
Nasdaq uplisting approval received and trading expected to commence
▼Equity OfferingCorporate
Pricing of $4 million underwritten public offering of 1,000,000 shares at $4.00 per share
▲MHRA MilestonePRPEx-US Regulatory
Completed scientific advice meeting with MHRA for PRP IMP manufacturing program
solid tumors (pancreatic, ovarian, colorectal cancers)source ↗
▲Manufacturing MilestonePRPCMC / Inspection
Successful reproduction run of manufacturing process for PRP drug substances trypsinogen and chymotrypsinogen
solid tumors (pancreatic, ovarian, colorectal cancers)source ↗
●MHRA MilestonePRPEx-US Regulatory
Scientific advice meeting requested with MHRA to discuss next steps for PRP
solid tumors (pancreatic, ovarian, colorectal cancers)source ↗
▲Patent GrantedPRPIP / Competition
Allowance of key patent application from European Patent Office covering pharmaceutical composition comprising trypsinogen and chymotrypsinogen
cancersource ↗
▲Orphan Drug DesignationPRPDesignation
FDA Orphan Drug Designation granted for PRP in pancreatic cancer
pancreatic cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How PPCB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every PPCB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PRP Orphan | advanced solid tumors | Phase 1b | 2026-09-29 | Greater than 90%, mean, tumor growth inhibition versus vehicle controls (p < 0.001); Median overall survival extension of more than 2.5-fold in treated animals compared with controlsRead More | Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial ResultsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kenyon Julian NormanDirector, Officer (Chief Scientific Officer) | Grant/Award | 3,420,000 3,420,005 held | $0.00 | 08/17/2021 |
Hedge Fund 13F Activity
Hedge Funds invested in PPCB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PPCB for Q2 2026. | ||||
PPCB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PPCB ranks across every disease it competes in
Competitive Position is a premium feature
See how PPCB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPPCB News
-PPCB
Oct 7, 2026▼ -0.9%today
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
Propanc Biopharma has reported promising preclinical data for its lead candidate PRP, demonstrating over 90% tumor growth inhibition in pancreatic cancer models. This contrasts with Revolution Medicines' daraxonrasib, which has shown significant survival benefits in clinical trials. PRP is set to enter a Phase 1b study in early 2027, targeting advanced solid tumors.
Read more →-PPCB
Sep 29, 2026Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
Propanc Biopharma announced a corporate update and year-end financial results for June 30, 2026. The company is set to initiate a Phase 1b study for its lead candidate PRP, targeting advanced solid tumors. Promising preclinical data indicate significant tumor growth inhibition and improved survival rates. Financially, Propanc raised $7.5 million to support its clinical development efforts.
Read more →-PPCB
Sep 22, 2026Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
Propanc Biopharma has released a comparative analysis of its lead candidate PRP against Erasca's ERAS-0015 for pancreatic ductal adenocarcinoma (PDAC). PRP demonstrated over 90% tumor-growth inhibition and a significant survival benefit in preclinical models. The company believes PRP's differentiation-based approach could work alongside RAS inhibitors to improve patient outcomes.
Read more →-PPCB
Sep 9, 2026Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
Propanc Biopharma announced plans to initiate a Phase 1b first-in-human study of PRP in February 2027. The study will involve up to 50 patients with advanced solid tumors, evaluating safety and preliminary antitumor activity. Manufacturing and regulatory preparations are progressing well, aiming to provide a new treatment option for patients with limited choices.
Read more →-PPCB
Aug 27, 2026▲ +108.4%on this news
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
Propanc Biopharma announced promising preclinical data for its lead candidate PRP in pancreatic cancer, demonstrating over 90% tumor growth inhibition and a median survival benefit exceeding 2.5-fold. The treatment also reduced metastatic burden and improved sensitivity to standard chemotherapy. The company is advancing towards a Phase 1b clinical trial focusing on advanced solid tumors.
Read more →-PPCB
Aug 18, 2026Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
Propanc Biopharma has announced the initiation of a Phase 1b clinical study for its cancer therapy PRP, targeting advanced solid tumors. The study will assess safety, tolerability, and preliminary activity in up to 40 patients. Preparatory activities are underway, with a Clinical Trial Application expected by Q4 2026. The CEO expressed confidence in the therapy's potential to improve cancer treatment outcomes.
Read more →-PPCB
Aug 12, 2026Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
Propanc Biopharma has highlighted its lead candidate PRP as a promising therapy for RAS-driven cancers, particularly pancreatic ductal adenocarcinoma (PDAC). The company plans to initiate a Phase 1b clinical study to evaluate PRP's efficacy in advanced cancer patients. PRP's unique mechanism targets cancer stem cells and promotes differentiation, potentially offering a long-term treatment option.
Read more →-PPCB
Aug 6, 2026▲ +15.3%on this news
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
Propanc Biopharma announced promising preclinical data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC). The treatment demonstrated over 90% tumor growth inhibition and extended median overall survival by more than 2.5 times in animal models. The company is accelerating its Phase 1b trial and expects to submit a clinical trial application soon.
Read more →-PPCB
Aug 5, 2026▲ +15.7%on this news· ran to +33% by day 1shared move
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
Propanc Biopharma has completed the first $500,000 tranche of its $5 million share repurchase program. The company aims to enhance shareholder value as it prepares for a Phase 1b study involving 40-45 advanced cancer patients. CEO James Nathanielsz emphasized the potential of their lead product, PRP, to transform metastatic cancer into a manageable condition.
Read more →-PPCB
Jul 21, 2026Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
Propanc Biopharma has published findings on recombinant trypsinogen and chymotrypsinogen in the journal Microbial Cell Factories. This research supports the development of rec-PRP, a backup clinical compound for treating metastatic cancer. The study indicates that these proenzymes can be produced at scale, potentially leading to effective treatments with a longer shelf life. The company aims to enter clinical trials for rec-PRP in early 2027.
Read more →-PPCB
Jul 7, 2026Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
Propanc Biopharma has signed a Memorandum of Understanding with Avance Clinical to support the Phase 1b clinical trial of its lead candidate, PRP, aimed at treating advanced solid tumors. The collaboration emphasizes a commitment to scientific rigor and patient safety. Avance Clinical will leverage its expertise to facilitate the trial's design and execution, aiming for efficient progression through clinical phases.
Read more →-PPCB
Jul 2, 2026▲ +22.9%on this newsshared move
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
Propanc Biopharma has launched a $5 million share repurchase program, starting with an initial tranche of $500,000. CEO James Nathanielsz highlighted the company's belief in the transformative potential of its lead asset, PRP, for treating metastatic cancer. The program allows for flexible share buybacks based on market conditions and reflects the company's commitment to enhancing shareholder value.
Read more →-PPCB
Jun 16, 2026▼ -10.2%on this news· ran to -31% by day 3
Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
Propanc Biopharma's CEO, James Nathanielsz, visited a European CDMO to prepare for GMP production of PRP for a Phase 1b study targeting advanced cancer patients. The visit aimed to solidify the partnership and discuss project timelines, including pre-production and engineering runs. The company anticipates submitting a clinical trial application in Australia in 2026.
Read more →-PPCB
Jun 11, 2026▲ +80%on this newsshared move
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
Propanc Biopharma has announced a $5 million share repurchase program, reflecting its confidence in the company's intrinsic value. This decision comes as the company progresses its lead asset, PRP, towards a pivotal Phase 1b clinical trial for metastatic cancer. The FDA has granted Orphan Drug Designation for PRP, enhancing its market potential.
Read more →-PPCB
Jun 2, 2026Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain
Propanc Biopharma's CEO, James Nathanielsz, attended a keynote address at the University of Granada, focusing on rejuvenation and health in an ageing society. The event featured Dr. Juan Carlos Izpisúa, a leading scientist in regenerative medicine. Propanc's ongoing research aims to develop treatments targeting age-related diseases, with their lead product PRP set to enter a Phase 1b study.
Read more →-PPCB
May 19, 2026Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
Propanc Biopharma has engaged a European CDMO for GMP production of its lead asset, PRP, ahead of a Phase 1b, First-In-Human study targeting 30-40 advanced cancer patients. The therapy aims to induce differentiation in cancer cells rather than directly killing them, potentially offering a novel treatment approach. The company plans to file a clinical trial application later this year.
Read more →-PPCB
May 14, 2026▼ -21.4%on this newsshared move
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
Propanc Biopharma has approved a 1-for-25 reverse stock split to comply with Nasdaq listing requirements. Effective May 18, 2026, the split will reduce the number of outstanding shares significantly. The company aims to enhance its market position and advance its lead product candidate, PRP, into a Phase 1b clinical study for advanced cancer patients.
Read more →-PPCB
Mar 24, 2026▼ -5.9%on this news
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
Propanc Biopharma has entered a multi-year research collaboration with the Universities of Jaén and Granada in Spain, focusing on anti-aging and cancer research. This partnership aims to evaluate a senescence-modulating compound and support claims related to recently filed patents. The collaboration is expected to enhance Propanc's intellectual property and advance its lead asset, PRP, towards clinical studies.
Read more →-PPCB
Mar 3, 2026▼ -5.2%on this news
Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
Propanc Biopharma's lead asset, PRP, demonstrates over 85% tumor growth inhibition in preclinical pancreatic cancer models. The investigational therapy targets cancer stem cells and aims to improve treatment outcomes while minimizing side effects. With a Phase 1b trial slated for 2026, the company is optimistic about PRP's potential to redefine cancer care.
Read more →-PPCB
Feb 18, 2026Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
Propanc Biopharma has provided a corporate update and reported its half-yearly financial results for 2025/26. The company has filed four provisional patent applications to enhance its intellectual property portfolio and published research on the impact of proenzymes on pancreatic cancer. Additionally, a $100 million private placement has been secured to support clinical development, with plans for a Phase 1b study of its lead asset, PRP.
Read more →About Propanc Biopharma, Inc.
Headquarters302/6 BUTLER STREET, CAMBERWELL, VICTORIA, C3, 3124
BIOPHARMAWATCH ELITE PLUS
Trade the next PPCB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime